The role of the downstream signal sequences in the maturation of the HBV middle surface glycoprotein: Development of a novel therapeutic vaccine candidate

Virology

Volumn 365, Issue 1, 2007, Pages 10-19

  Liu, Yuanjie ^a   Simsek, Ender ^a   Norton, Pamela ^a   Sinnathamby, Gomathinayagam ^b   Philip, Ramila ^b   Block, Timothy ^a   Zhou, Tianlun ^b   Mehta, Anand ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b BARUCH S BLUMBERG INSTITUTE   (United States)

Author keywords

Antigen presentation; Glycosylation; Hepatitis B virus; Secretion; Vaccine

Indexed keywords

ENVELOPE PROTEIN; GLYCOPROTEIN; PROTEASOME; SIGNAL PEPTIDE; VIRUS VACCINE; VIRUS VECTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOSOL; DRUG SCREENING; ENDOPLASMIC RETICULUM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE DELETION; GENE MUTATION; GLYCOSYLATION; HEPATITIS B VIRUS; HYDROPHOBICITY; MICROSOME; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROCESSING;

CELL LINE; ENDOPLASMIC RETICULUM; GLYCOSYLATION; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; MEMBRANE GLYCOPROTEINS; PROTEIN SORTING SIGNALS; VACCINES; VIRION; VIRUS ASSEMBLY;

HEPATITIS B VIRUS;

EID: 34250194001     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2007.03.042     Document Type: Article

References (18)

1. Block T.M., Mehta A.S., Blumberg B.S., and Dwek R.A. Does rapid oligomerization of hepatitis B envelope proteins play a role in resistance to proteasome degradation and enhance chronicity?. DNA Cell Biol. 25 3 (2006) 165-170
2. Bruss V., Lu X., Thomssen R., and Gerlich W.H. Post-translational alterations in transmembrane topology of the hepatitis B virus large envelope protein. EMBO J. 13 10 (1994) 2273-2279
3. Comunale M.A., Mattu T.S., Lowman M.A., Evans A.A., London W.T., Semmes O.J., Ward M., Drake R., Romano P.R., Steel L.F., Block T.M., and Mehta A. Comparative proteomic analysis of de-N-glycosylated serum from hepatitis B carriers reveals polypeptides that correlate with disease status. Proteomics 4 3 (2004) 826-838
4. Dwek R.A., Edge C.J., Harvey D.J., Wormald M.R., and Parekh R.B. Analysis of glycoprotein-associated oligosaccharides. Annu. Rev. Biochem. 62 4 (1993) 65-100
5. Dwek R.A., Butters T.D., Platt F.M., and Zitzmann N. Targeting glycosylation as a therapeutic approach. Nat. Rev., Drug Discov. 1 1 (2002) 65-75
6. Eble B.E., Lingappa V.R., and Ganem D. Hepatitis B surface antigen: an unusual secreted protein initially synthesized as a transmembrane polypeptide. Mol. Cell. Biol. 6 5 (1986) 1454-1463
7. Eble B.E., MacRae D.R., Lingappa V.R., and Ganem D. Multiple topogenic sequences determine the transmembrane orientation of the hepatitis B surface antigen. Mol. Cell. Biol. 7 10 (1987) 3591-3601
8. Eble B.E., Lingappa V.R., and Ganem D. The N-terminal (pre-S2) domain of a hepatitis B virus surface glycoprotein is translocated across membranes by downstream signal sequences. J. Virol. 64 3 (1990) 1414-1419
9. Gerlich W.H., Heermann K.H., and Lu X. Functions of hepatitis B surface proteins. Arch. Virol., Suppl. 4 (1992) 129-132
10. Golovina T.N., Morrison S.E., and Eisenlohr L.C. The impact of misfolding versus targeted degradation on the efficiency of the MHC class I-restricted antigen processing. J. Immunol. 174 5 (2005) 2763-2769
11. Karttunen J., and Shastri N. Measurement of ligand-induced activation in single viable T cells using the lacZ reporter gene. Proc. Natl. Acad. Sci. U.S.A. 88 9 (1991) 3972-3976
12. Karttunen J., Sanderson S., and Shastri N. Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc. Natl. Acad. Sci. U.S.A. 89 13 (1992) 6020-6024
13. Lambert C., and Prange R. Dual topology of the hepatitis B virus large envelope protein: determinants influencing post-translational pre-S translocation. J. Biol. Chem. 276 25 (2001) 22265-22272
14. Prange R., and Streeck R.E. Novel transmembrane topology of the hepatitis B virus envelope proteins. EMBO J. 14 2 (1995) 247-256
15. Schwarz K., de Giuli R., Schmidtke G., Kostka S., van den Broek M., Kim K.B., Crews C.M., Kraft R., and Groettrup M. The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses. J. Immunol. 164 12 (2000) 6147-6157
16. Simsek E., Mehta A., Zhou T., Dwek R.A., and Block T. Hepatitis B virus large and middle glycoproteins are degraded by a proteasome pathway in glucosidase-inhibited cells but not in cells with functional glucosidase enzyme. J. Virol. 79 20 (2005) 12914-12920
17. Werr M., and Prange R. Role for calnexin and N-linked glycosylation in the assembly and secretion of hepatitis B virus middle envelope protein particles. J. Virol. 72 1 (1998) 778-782
18. Wherry E.J., McElhaugh M.J., and Eisenlohr L.C. The induction of virus-specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of epitope are attained. J. Immunol. 163 7 (1999) 3735-3745